BME100 f2015:Group1 1030amL2

BME 100 Fall 2015	Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
OUR TEAM Name: Nichole Torgerson Name: Alarmel Sira Name: Matt Chrest Name: Lindsey O'Brien Name: Jacob Aperi Name: Michael "Otis" Clyne LAB 2 WRITE-UP Descriptive Statistics Experiment 1 - Human Trial Dosages 0mg 5mg 10mg 15mg Average 3.834 8.932 61.622 657.941 Standard Deviation 1.52301 1.593932 30.11069 212.943 Standard Error 0.50767 0.531311 10.0369 70.98099 Experiment 2 - Rat Trial Dosages 0mg 10mg Average 10.516 11.112 Standard Deviation 2.225552 7.402886 Standard Error 0.995297 3.310671 Results Experiment 1 - Human Trial ‎Experiment 2 - Rat Trial Analysis Experiment 1-Human Trial The graphs show there is significant difference between the dosages. This means that the increase in dosage of Inflammotin increases the inflammation in elderly humans. The LPS has a positive correlation with Inflammotin levels. Experiment 2-Rat Trial The graphs show there is no significance between dosages. The increase in dosages do not have an effect on the Inflammation levels, therefore there is no correlation between the two. Summary/Discussion When the two experiments were formed, there was an effect on elderly people in increasing the dosages, but there was no effect on the rats when the dosages were increased. A reason there is an effect in humans is only because they have a better response to the Inflammotin where the rats do not have as good of a response. Another reason is because only humans have the protein in their body, that causes a change in inflammation.